Tagged with OP

Europe As part of the EU’s Pharmaceutical Strategy for Europe, the European Commission has come out with a set of proposals to revise EU pharmaceutical legislation. The reforms, which aim to make medicines more available and accessible across Europe by reducing regulatory exclusivity, speeding up review processes and reinforcing supply chains…

Europe In conversation at DIA Europe 2023 in Basel, European Medicines Agency Executive Director Emer Cooke looks back at the lessons EMA has taken from the COVID-19 pandemic response, outlines the Agency’s approach to antimicrobial resistance, and highlights how it hopes to contribute to a stronger European clinical trials ecosystem.  …

Belgium Despite the thriving life sciences ecosystem that has made Belgium one of the top European destinations for clinical trials, the country continues to grapple with considerable access challenges and remains behind many of its European counterparts. In a recent roadmap, the minister of health set out to improve the country’s…

Global The UHC2030 Private Sector Constituency (UHC2030 PSC), which is hosted by the World Bank Group, has released a statement on the private sector commitments toward universal health coverage (UHC), ahead of Multi-stakeholder Hearings on UHC that will take place in New York on 9th May 2023. The IFPMA’s Thomas Cueni…

Poland With a geostrategic location and easy access to both Western Europe and the rest of the emerging Central and Eastern Europe (CEE) region, Poland represents the sixth largest pharma market in the European Union. Having demonstrated steady year-on-year growth, the market, with its strong generics-centred local players, is set to…

China China has made major healthcare strides over the past decade with regulatory reforms, infrastructure improvements, and the advancement of universal healthcare. While the COVID-19 pandemic revealed the need for further reform, the country continues to pursue the healthcare transformation goals established in its Health China 2030 program. These aspirations are…

Global Shawview Consulting’s Brendan Shaw casts his eye over the increased industry focus on Environment, Social, and Governance (ESG) issues in recent years, urging pharma companies to deliver on their ESG promises and capitalise on doing good while achieving commercial success.   It is our choices, Harry, that show what we truly…

Africa The third and final piece in Lenias Hwenda of Medicines for Africa’s series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come (read part one here and part two here). Here, Hwenda examines the persistent challenge of HIV/AIDS…

Global In 2023, we face a new digital relations landscape where a customer and a brand more and more rely on personal data exchange and unique communication channels. In this new reality, marketing means are shifting towards direct communication and personalization, and generic campaigns are making way for communications that target…

Global Takeda’s Mwana Lugogo and Pfizer’s Rady Johnson, the current and former chairs of the IFPMA Ethics & Business Integrity Committee and Chief Ethics & Compliance Officers Roundtable respectively, highlight the IFPMA’s new ‘Ethoscope’ initiative, which aims to promote ethics and business integrity throughout the industry to sustain and develop trust.…

Europe Alexander Natz of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) casts his eye over the potential effects of the upcoming EU Pharmaceutical Legislation for small- and medium-sized enterprises in Europe. Natz feels that Europe is at a crossroads in terms of its positioning as a driver of innovation and calls…

Belgium With over 140 operating biotech companies representing almost a quarter of Europe’s biotech market and a strong network of universities and research institutes, Belgium boasts a solid biotech ecosystem that continues to thrive despite recent downturns in biotech financing. Beyond more well-known players like Argenx, acquired by Sanofi, and Galapagos,…